Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer / 中国医学科学院学报
Acta Academiae Medicinae Sinicae
;
(6): 305-308, 2014.
Article
Dans Anglais
| WPRIM
| ID: wpr-329829
ABSTRACT
<p><b>OBJECTIVE</b>To compare the efficacy and safety between liposome-paclitaxel plus carboplatin (LPC) and paclitaxel plus carboplatin (PC) as first-line treatment for advanced non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Totally 54 chemotherapy-naive NSCLC patients were equally and randomly assigned into LPC group and PC group. Liposome-paclitaxel was injected on D1 at a dosage of 175 mg/m(2); the same dose and administration with paclitaxel injection in the PC group for a maximum of 2 cycles. The efficacy and adverse reactions after 2 cycles of chemotherapy were compared between these two groups.</p><p><b>RESULTS</b>The overall response rate (CR+PR) was 44.4% in the LPC group and 33.3% in the PC group after 2 cycles of chemotherapy respectively (P=0.577). In the LPC group and PC group, the incidences of myelodepression was 81.5% and 63.0%, respectively (P=0.080), gastrointestinal toxicity was 96.3% and 77.8% respectively (P=0.100), and allergic reactions was 0 and 11.1%, respectively (P=0.000). The median time to progression was 6 months and 5 months, respectively (P=0.420).</p><p><b>CONCLUSION</b>LPC group has the same efficacy with PC group and less adverse reactions than PC group.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Carboplatine
/
Résultat thérapeutique
/
Paclitaxel
/
Carcinome pulmonaire non à petites cellules
/
Traitement médicamenteux
/
Liposomes
/
Tumeurs du poumon
Limites du sujet:
Adulte
/
Adulte très âgé
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Acta Academiae Medicinae Sinicae
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS